Accounts Receivable, after Allowance for Credit Loss, Current of Perspective Therapeutics, Inc. from 30 Jun 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Perspective Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 30 Jun 2011 to 30 Sep 2025.
  • Perspective Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Sep 2025 was $179,000, a 18% decline year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Perspective Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $179,000 -$38,000 -18% 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $225,000 +$83,000 +58% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $78,000 -$921,000 -92% 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $116,000 -$1,049,000 -90% 31 Dec 2024 10-Q 10 Nov 2025 2025 Q3
Q3 2024 $217,000 -$1,514,000 -87% 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $142,000 -$971,000 -87% 30 Jun 2024 10-Q 13 Aug 2024 2024 Q2
Q1 2024 $999,000 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $1,165,000 -$198,000 -15% 31 Dec 2023 10-K/A 28 Mar 2025 2024 FY
Q3 2023 $1,731,000 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $1,113,000 -$495,000 -31% 30 Jun 2023 10-Q 11 Aug 2023 2023 Q2
Q4 2022 $1,363,000 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q2 2022 $1,608,000 -$405,000 -20% 30 Jun 2022 10-KT 01 May 2023 2023 Q1
Q2 2021 $2,013,000 30 Jun 2021 10-KT 01 May 2023 2023 Q1
Q3 2015 $1,130,540 +$168,281 +17% 30 Sep 2015 10-Q 09 Nov 2015 2016 Q1
Q2 2015 $1,049,041 +$135,992 +15% 30 Jun 2015 10-Q 09 Nov 2015 2016 Q1
Q1 2015 $1,038,473 +$233,147 +29% 31 Mar 2015 10-Q 15 May 2015 2015 Q3
Q4 2014 $797,381 -$119,841 -13% 31 Dec 2014 10-Q 17 Feb 2015 2015 Q2
Q3 2014 $962,259 +$3 0% 30 Sep 2014 10-Q 14 Nov 2014 2015 Q1
Q2 2014 $913,049 -$10,731 -1.2% 30 Jun 2014 10-K 14 Sep 2015 2015 FY
Q1 2014 $805,326 -$24,709 -3% 31 Mar 2014 10-Q 15 May 2014 2014 Q3
Q4 2013 $917,222 +$261,054 +40% 31 Dec 2013 10-Q 14 Feb 2014 2014 Q2
Q3 2013 $962,256 +$117,158 +14% 30 Sep 2013 10-Q 14 Nov 2013 2014 Q1
Q2 2013 $923,780 +$58,724 +6.8% 30 Jun 2013 10-K 29 Sep 2014 2014 FY
Q1 2013 $830,035 -$23,062 -2.7% 31 Mar 2013 10-Q 15 May 2013 2013 Q3
Q4 2012 $656,168 -$172,696 -21% 31 Dec 2012 10-Q 14 Feb 2013 2013 Q2
Q3 2012 $845,098 -$127,331 -13% 30 Sep 2012 10-Q 14 Nov 2012 2013 Q1
Q2 2012 $865,056 +$72,221 +9.1% 30 Jun 2012 10-K 30 Sep 2013 2013 FY
Q1 2012 $853,097 31 Mar 2012 10-Q 15 May 2012 2012 Q3
Q4 2011 $828,864 31 Dec 2011 10-Q 14 Feb 2012 2012 Q2
Q3 2011 $972,429 30 Sep 2011 10-Q/A 13 Dec 2011 2012 Q1
Q2 2011 $792,835 30 Jun 2011 10-K/A 26 Oct 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.